Fred joined Foresite Capital in December 2020 and is contributing as a senior R&D advisor in the evaluation group.
Fred most recently served as Chief Medical Officer (CMO) and Head of Global Regulatory Affairs at Intarcia in Boston. He had previously been CMO at Rhythm Pharma since 2014, initiating Phase 3 global development programs with Imcivree (setmelanotide) for rare forms of genetic obesity. Prior to these biotech roles, Fred had 14 years of drug development experience at Bristol-Myers Squibb (BMS), ultimately serving as Senior Vice President of Cardiovascular (CV) & Metabolic Development with broad R&D responsibilities. While at BMS, teams under Fred’s leadership advanced clinical development and achieved global regulatory approvals of Onglyza (saxagliptin), Farxiga (dapagliflozin), Bydureon (exenatide XR), Eliquis (apixaban) and Myalept (metreleptin). Fred’s initial industry roles were in early- and late-stage development of nuclear hormone receptor and other metabolic programs at GlaxoWellcome in RTP.
Prior to joining biotech/pharma, Fred was on the medical faculty at UNC-Chapel Hill in Internal Medicine and Genetics. Fred is boarded in both internal medicine and endocrinology, completing residency, fellowship training and chief residency at Washington University in St. Louis. He received an M.D. from Harvard Medical School and a B.A. in English from Yale University [magna cum laude, with distinction for the best senior thesis (on William Faulkner)].